Apotex files US antitrust claims against Amarin over Vascepa
MLex Summary: Apotex filed a US complaint accusing Amarin Pharma of illegally delaying generic competition for the branded cardiovascular drug Vascepa. It claims Amarin used exclusivity agreements to prevent any suppliers...To view the full article, register now.
Already a subscriber? Click here to view full article